↑ 薬物リストへ　← 戻る

Docosahexaenoic acid    (DrugBank: Docosahexaenoic acid)

7 diseases
告示番号疾患名（ページ内リンク）臨床試験数
6パーキンソン病1
49全身性エリテマトーデス1
90網膜色素変性症2
94原発性硬化性胆管炎1
240フェニルケトン尿症2
299嚢胞性線維症5
301黄斑ジストロフィー1

6. パーキンソン病　［臨床試験数：2,123，薬物数：2,046（DrugBank：324），標的遺伝子数：183，標的パスウェイ数：198］
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,123 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01563913
(ClinicalTrials.gov)		October 201216/3/2012Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty AcidsReducing Dyskinesia in Parkinson Disease With Omega-3 Fatty AcidsParkinson's DiseaseDrug: Docosahexaenoic Acid (DHA);Drug: PlaceboVA Office of Research and DevelopmentOregon Health and Science UniversityCompleted21 Years99 YearsAll33Phase 1United States

49. 全身性エリテマトーデス　［臨床試験数：827，薬物数：638（DrugBank：168），標的遺伝子数：108，標的パスウェイ数：191］
Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 827 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2004-004404-21-GB
(EUCTR)		10/12/200417/02/2005Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences - Fish oils in LupusOmega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences - Fish oils in Lupus Systemic Lupus ErythematosusTrade Name: Omacor
Product Name: Omacor
INN or Proposed INN: Eicosapentaenoic acid
INN or Proposed INN: Docosahexaenoic acid
INN or Proposed INN: alpha-tocopherol		GreenPark Healthcare TrustQueens University BelfastNot RecruitingFemale: yes
Male: yes		60Phase 4United Kingdom

90. 網膜色素変性症　［臨床試験数：103，薬物数：158（DrugBank：42），標的遺伝子数：52，標的パスウェイ数：107］
Searched query = "Retinitis pigmentosa", "Rod dystrophy", "Rod-Cone Dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 103 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00100230
(ClinicalTrials.gov)		September 200427/12/2004DHA and X-Linked Retinitis PigmentosaInvestigation of Effectiveness and Safety of High Dose Docosahexaenoic Acid (DHA) in X-Linked Retinitis PigmentosaRetinitis Pigmentosa;X-linked Genetic DiseasesDrug: docosahexaenoic acid OR corn/soy oil placeboRetina Foundation of the SouthwestFoundation Fighting Blindness;DSM Nutritional Products, Inc.Completed7 Years32 YearsMale78Phase 2United States
2NCT00004827
(ClinicalTrials.gov)		March 199624/2/2000Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis PigmentosaRetinitis PigmentosaDrug: docosahexaenoic acidRetina Foundation of the SouthwestNULLCompletedN/AN/AMale46N/ANULL

94. 原発性硬化性胆管炎　［臨床試験数：134，薬物数：105（DrugBank：37），標的遺伝子数：18，標的パスウェイ数：131］
Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 134 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00325013
(ClinicalTrials.gov)		December 200510/5/2006Evaluation of DHA for the Treatment of PSCEvaluation of Docosahexaenoic Acid (DHA) for the Treatment of Primary Sclerosing Cholangitis (PSC)Primary Sclerosing Cholangitis;ColitisDrug: Docosahexaenoic Acid (DHA)Beth Israel Deaconess Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed18 Years80 YearsBoth10Phase 1United States

240. フェニルケトン尿症　［臨床試験数：125，薬物数：95（DrugBank：11），標的遺伝子数：1，標的パスウェイ数：5］
Searched query = "Phenylketonuria", "PKU", "Phenylalanine hydroxylase deficiency", "PAH deficiency", "Tetrahydrobiopterin deficiency", "BH4 deficiency", "BH4 reactive hyper pheemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 125 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00909012
(ClinicalTrials.gov)		May 200922/4/2009Quantitative Requirements of Docosahexaenoic Acid for Neural Function in Children With PhenylketonuriaQuantitative Requirements of Docosahexaenoic Acid for Neural Function in Children With PhenylketonuriaPhenylketonuriaDietary Supplement: high oleic sunflower oil;Dietary Supplement: microalgal oilLudwig-Maximilians - University of MunichEuropean UnionCompleted5 Years13 YearsAll114N/AGermany;Italy;Spain;United Kingdom
2NCT00892554
(ClinicalTrials.gov)		June 20071/5/2009The Effect of Supplemental Docosahexaenoic Acid (DHA) on Neurocognitive Outcomes in Teen and Adult Women With Phenylketonuria(PKU)The Impact of Docosahexaenoic Acid on Neuropsychological Status in Females With PhenylketonuriaPhenylketonuriaDietary Supplement: Docosahexaenoic Acid;Dietary Supplement: Corn/soy oilEmory UniversityAtlanta Clinical and Translational Science InstituteCompleted12 Years50 YearsFemale33N/AUnited States

299. 嚢胞性線維症　［臨床試験数：1,592，薬物数：1,539（DrugBank：255），標的遺伝子数：81，標的パスウェイ数：162］
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 1,592 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03045198
(ClinicalTrials.gov)		March 20122/2/2017Effect of Azithromycin on Fatty Acids in CFEffect of Azithromycin on Lipoproteins and Docosahexaenoic Acid in Patients With Cystic FibrosisCystic FibrosisDrug: AzithromycinUniversity Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)University of Bonn;University Hospital, FrankfurtUnknown status10 Years60 YearsAll20Phase 4NULL
2NCT01783613
(ClinicalTrials.gov)		October 201131/1/2013Eficacy of Long-term Suplementation With Docosahexaenoic Acid in Patients With Cystic FibrosisStudy of the Eficacy of Long-term Suplementation With Docosahexaenoic Acid on Pulmonary, Sistemic and Intestinal Inflammation in Patients With Cystic FibrosisCystic FibrosisDietary Supplement: Docosahexaenoic acid administration: 50 mg/kg/day during 12 months;Dietary Supplement: Placebo: 50 mg/kg/day during 12 monthsFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalNULLCompleted2 Months100 YearsAll96N/ASpain
3EUCTR2010-020516-11-IT
(EUCTR)		16/09/201028/09/2010EXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - NDEXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - ND CYSTIC FIBROSIS AND PANCREATIC INSUFFICIENCY
MedDRA version: 9.1;Level: PT;Classification code 10033628
MedDRA version: 9.1;Classification code 10011762		Trade Name: PREFOLIC*30CPR GASTROR 15MG
INN or Proposed INN: Detoxifying agents for antineoplastic treatment
Trade Name: INDUSIL*OS GTT FL 30MG+FL 15ML
INN or Proposed INN: Cobamamide		AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		Italy
4NCT02690857
(ClinicalTrials.gov)		May 201016/2/2016Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)Efficacy of Docosahexanoic Acid on Lipid Peroxidation in Subjects With Cystic FibrosisCystic FibrosisDrug: Docosahexaenoic acid;Drug: Sunflower OilHospices Civils de LyonNULLCompleted6 Years30 YearsMale10Phase 2NULL
5NCT00530244
(ClinicalTrials.gov)		March 200313/9/2007Use of Formula Fortified With DHA in Infants With Cystic FibrosisThe Effect of Formula Fortified With Docosahexaenoic Acid (DHA) on Infants With Cystic Fibrosis (CF)Cystic FibrosisDietary Supplement: Docosahexaenoic acid (DHA);Dietary Supplement: Standard formula (Enfamil)University of Massachusetts, WorcesterCystic Fibrosis FoundationCompletedN/A56 DaysAll76N/AUnited States

先頭へ


301. 黄斑ジストロフィー　［臨床試験数：41，薬物数：47（DrugBank：12），標的遺伝子数：12，標的パスウェイ数：66］
Searched query = "Macular dystrophy", "Best disease", "Stargardt disease", "Cone dystrophy", "Cone rod dystrophy", "X-linked juvenile retinoschisis", "Central areolar choroidal dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 41 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00060749
(ClinicalTrials.gov)		May 5, 20039/5/2003Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular DystrophyInvestigation of the Effect of Dietary Docosahexaenoic Acid (DHA) Supplementation on Macular Function in Subjects With Autosomal Dominant Stargardt-Like and Autosomal Recessive Stargardt Macular DystrophyMacular DegenerationDrug: Docosahexaenoic Acid (DHA) Dietary SupplementNational Eye Institute (NEI)NULLCompletedN/AN/AAll22Phase 1United States

先頭へ